複雑冠動脈病変におけるInspiron EVO薬剤溶出ステントのブラジル前向きレジストリ (PCI EVOlution)
複雑冠動脈病変におけるInspiron EVO薬剤溶出ステント全国前向きレジストリ
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Post-marketing, observational, prospective, multi-center, non-randomized, single-arm registry that will include all patients who receive the Inspiron™ EVO stent at participating sites and meet the eligibility criteria.
Up to 2,000 patients are expected to be enrolled across 12 research sites in Brazil. Participants' demographic, procedural, and follow-up data will be collected for up to 12 months in this study.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Marco Aurélio A Costa, MD, PhD
- 電話番号:+1 216 903-9327
- メール:marco.costa@scitechmed.com
研究連絡先のバックアップ
- 名前:Ana Paula B Pellaquim, MSc.
- 電話番号:+55 62 9471-4439
- メール:aalmeida@scitechmed.com
研究場所
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90610000
- 募集
- Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
-
コンタクト:
- Paulo Ricardo A Caramori, MD
- 電話番号:+55 51 99982 0766
- メール:caramori@cardiarte.com.br
-
コンタクト:
- Rosa Homem
- 電話番号:+55 51 99679 8040
- メール:cer.pesquisaclinica@gmail.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions treated with the Inspiron™ EVO Drug-Eluting Stent.
説明
Inclusion Criteria:
- Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).
- Individuals who provide consent and are willing to comply with the follow-up protocol.
- Individuals who received treatment with the Inspiron™ EVO Stent.
- Individuals with lesions ≥ 30 mm in length (Subprotocol 1).
- Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC/AHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).
- Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).
- Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).
Exclusion Criteria:
- Lesions in saphenous vein grafts or internal mammary grafts.
- Contraindication to the use of a drug-eluting stent.
- Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Experimental: Percutaneous coronary intervention (PCI)
Patients with symptomatic ischemic heart disease due to lesions in the native coronary artery and restenotic lesions treated with the Inspiron™ EVO drug-eluting stent. |
Percutaneous coronary intervention (PCI) using the Inspiron EVO Drug-Eluting Stent, which has a reduced crimped profile, providing greater safety and facilitating lesion crossing. In addition, the design is optimized to provide increased radial strength. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Device success
時間枠:Initial procedure
|
Device success (at the lesion level) is defined as the successful delivery, balloon expansion, and implantation of the first device at the target lesion (with multiple attempts using the same device permitted), successful withdrawal of the delivery system, and achievement of a final in-stent residual stenosis of <20% |
Initial procedure
|
|
Acute Clinical Success of Percutaneous Coronary Intervention (PCI)
時間枠:Up to 24 hours
|
Defined as the absence of major adverse in-hospital cardiac events (death, myocardial infarction, or repeat coronary revascularization of the target lesion). |
Up to 24 hours
|
|
MACE (Major Adverse Cardiac Events) rate
時間枠:12 months
|
Defined as the combination of cardiac death, myocardial infarction (MI), or revascularization of the target lesion (TLR). |
12 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Target Lesion Revascularization (TLR) rate
時間枠:12 months
|
TLR is defined as any percutaneous reintervention of the target lesion, including the 5 mm proximal and 5 mm distal segments of the stent, or revascularization of the target vessel, performed for clinical reasons due to restenosis or occlusion of the target lesion. |
12 months
|
|
Target vessel revascularization rate (TVR)
時間枠:12 months
|
TVR is defined as revascularization of any segment of the target coronary artery. |
12 months
|
|
Target Vessel Failure Rate (TVF)
時間枠:12 months
|
Defined as a combination of MI, TLR, or cardiovascular death related to the target vessel. If it is not possible to determine with certainty whether the MI or death was related to the target vessel, the case is considered a TVF. |
12 months
|
|
Rate of definite, probable, and possible stent thrombosis (ST)
時間枠:12 months
|
Stent thrombosis is classified as definite, probable, or possible: definite requires angiographic or pathological confirmation; probable includes unexplained death within 30 days or myocardial infarction related to the stented territory without angiographic confirmation; and possible refers to any unexplained death occurring from 30 days after implantation until the end of follow-up. |
12 months
|
|
Cardiovascular mortality
時間枠:12 months
|
Any death due to an immediate cardiac cause (e.g., myocardial infarction, low-output heart failure, fatal arrhythmia), unwitnessed death, death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death. |
12 months
|
|
Late in-segment luminal loss (including the in-stent portion and the 5-mm proximal and distal edges)
時間枠:6 months
|
Defined as the difference between the in-segment minimum luminal diameter (MLD) (including the in-stent portion and the 5-mm proximal and distal edges) after the procedure and the MLD at the 6-month follow-up, as determined by quantitative angiography. |
6 months
|
|
Percent Area Stenosis (%AS)
時間枠:6 months
|
Defined as the ratio between the neointimal hyperplasia area and the stent area multiplied by 100 at the 6-month follow-up. |
6 months
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Paulo Ricardo A Caramori, MD、Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- SCI-EV-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。